Phase I study of ROR1-specific CAR-T cells in advanced hematopoietic and epithelial malignancies

Last Updated: Tuesday, May 13, 2025

A phase I study evaluating the safety of ROR1 CAR T cells. The researchers observed antitumor activity in chronic lymphocytic leukemia, but this was limited in triple-negative breast cancer and non–small cell lung cancer. The ROR1 CAR-T cells were well tolerated in most patients, although there was one dose-limiting toxicity at dose level 4 in a patient with advanced non–small cell lung cancer.

Clinical Cancer Research

Leukemia

Anti-CD19 CAR-T cell therapy for acquired hemophilia A

Brain

Current state and perspectives of CAR T-cell therapy in central nervous system diseases

Clinical Cancer Research

Phase I study of ROR1-specific CAR-T cells in advanced hematopoietic and epithelial malignancies

Blood

CD70 CAR T cells secreting an anti-CD33/anti-CD3 dual-targeting antibody overcome antigen heterogeneity in AML

Oncogene

Preclinical application of a CD155 targeting chimeric antigen receptor T-cell therapy for digestive system cancers

Critical Reviews in Oncology/Hematology

Chimeric antigen receptor T cell immunotherapy for gynecological malignancies

International Immunopharmacology

The paths toward immunotherapy of esophageal cancer: An overview of clinical trials

Trends in Pharmacological Sciences

Boosting CAR-T cell therapy through vaccine synergy

Nature Medicine

Long-term outcomes of GD2-directed CAR-T cell therapy in patients with neuroblastoma

Blood Advances

Access barriers to anti-CD19+ CART therapy for NHL across a community transplant and cellular therapy network

CAR T-Cell Therapy Resource Center

Phase I study of ROR1-specific CAR-T cells in advanced hematopoietic and epithelial malignancies

Leukemia

Anti-CD19 CAR-T cell therapy for acquired hemophilia A

Brain

Current state and perspectives of CAR T-cell therapy in central nervous system diseases

Clinical Cancer Research

Phase I study of ROR1-specific CAR-T cells in advanced hematopoietic and epithelial malignancies

Blood

CD70 CAR T cells secreting an anti-CD33/anti-CD3 dual-targeting antibody overcome antigen heterogeneity in AML

Oncogene

Preclinical application of a CD155 targeting chimeric antigen receptor T-cell therapy for digestive system cancers

Critical Reviews in Oncology/Hematology

Chimeric antigen receptor T cell immunotherapy for gynecological malignancies

International Immunopharmacology

The paths toward immunotherapy of esophageal cancer: An overview of clinical trials

Trends in Pharmacological Sciences

Boosting CAR-T cell therapy through vaccine synergy

Nature Medicine

Long-term outcomes of GD2-directed CAR-T cell therapy in patients with neuroblastoma

Blood Advances

Access barriers to anti-CD19+ CART therapy for NHL across a community transplant and cellular therapy network

Transverse Myelitis With Paraplegia: An Atypical Manifestation of Neurotoxicity Following CAR T-Cell Therapy

CAR T-cell Infusion in an Outpatient Setting: An Ideal Option for Selected Patients When Available

B-Cell Aplasia, Hypogammaglobulinemia Can Result in Serious, Life-Threatening Infections

Fast Facts #12: BCMA Targets